XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.

ABSTRACT:

Objectives

Although platinum-based chemotherapy is widely used for advanced ovarian cancer (OC), genetic polymorphisms can influence the chemotherapeutic response. This study investigated the association between XRCC1 polymorphisms Arg194Trp, Arg280His, and Arg399Gln, and overall survival (OS) in OC patients who received platinum-based chemotherapy.

Methods

We systematically searched PubMed, Embase, the Cochrane library, Chinese National Knowledge Infrastructure, Wanfang, and Weipu databases for relevant studies from inception to October, 2017. OS was calculated using a random-effects model. Sensitivity, subgroup, and publication bias analyses were also performed.

Results

Five studies involving 1159 OC patients were included. When compared with 194ArgArg, 194TrpTrp (h

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC6250521 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature